The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma.
 
Kohei Shitara
Honoraria - Bristol-Myers Squibb; Takeda
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yung-Jue Bang
Consulting or Advisory Role - Alexo Therapeutics; Astellas Pharma; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Green Cross; Hanmi; Merck Serono; MSD Oncology; Novartis; Samyang
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Curis (Inst); Daiichi Sankyo (Inst); GC Pharma (Inst); Genentech/Roche (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Satoru Iwasa
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Seagen (Inst); Zymeworks (Inst)
 
Naotoshi Sugimoto
Research Funding - Astellas Pharma (Inst); BeiGene (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Solasia Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Min-Hee Ryu
Honoraria - AstraZeneca; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
 
Daisuke Sakai
Speakers' Bureau - Chugai Pharma
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo; Eisai (Inst); Incyte (Inst); Lilly Japan; Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Hyun Cheol Cheol Chung
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Celltrion; Gloria Biosciences; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical; Zymeworks
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono
Research Funding - Amgen (Inst); Beigene (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
 
Yasushi Omuro
Research Funding - Astellas Pharma (Inst); BeiGene (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Hisato Kawakami
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo Co. Ltd.,; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst)
 
Hiroshi Yabusaki
No Relationships to Disclose
 
Yasuhiro Sakamoto
No Relationships to Disclose
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Koichiro Inaki
Employment - Daiichi Sankyo
 
Yusuke Kuwahara
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Fumitaka Suto
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Masahiro Sugihara
Employment - Daiichi-Sankyo Co., LTD.
 
Kaku Saito
Employment - Daiichi Sankyo
 
Akihito Kojima
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)